DK1165078T3 - Fremgangsmåder til induktion af cancercelledöd og tumorregression - Google Patents
Fremgangsmåder til induktion af cancercelledöd og tumorregressionInfo
- Publication number
- DK1165078T3 DK1165078T3 DK00921765T DK00921765T DK1165078T3 DK 1165078 T3 DK1165078 T3 DK 1165078T3 DK 00921765 T DK00921765 T DK 00921765T DK 00921765 T DK00921765 T DK 00921765T DK 1165078 T3 DK1165078 T3 DK 1165078T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- cancer cell
- cell death
- tumor regression
- inducing cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/289,255 US6316462B1 (en) | 1999-04-09 | 1999-04-09 | Methods of inducing cancer cell death and tumor regression |
PCT/US2000/009124 WO2000061145A1 (en) | 1999-04-09 | 2000-04-06 | Methods of inducing cancer cell death and tumor regression |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1165078T3 true DK1165078T3 (da) | 2007-04-16 |
Family
ID=23110723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00921765T DK1165078T3 (da) | 1999-04-09 | 2000-04-06 | Fremgangsmåder til induktion af cancercelledöd og tumorregression |
Country Status (24)
Country | Link |
---|---|
US (1) | US6316462B1 (da) |
EP (1) | EP1165078B1 (da) |
JP (1) | JP2003529540A (da) |
CN (1) | CN100421661C (da) |
AR (1) | AR023400A1 (da) |
AT (1) | ATE347360T1 (da) |
AU (1) | AU783177B2 (da) |
BR (1) | BR0009670A (da) |
CA (1) | CA2364675A1 (da) |
CY (1) | CY1107545T1 (da) |
DE (1) | DE60032226T2 (da) |
DK (1) | DK1165078T3 (da) |
ES (1) | ES2275505T3 (da) |
HK (1) | HK1038512B (da) |
HU (1) | HUP0200773A3 (da) |
MX (1) | MXPA01010211A (da) |
MY (1) | MY120841A (da) |
NO (1) | NO329133B1 (da) |
NZ (1) | NZ514628A (da) |
PE (1) | PE20010025A1 (da) |
PT (1) | PT1165078E (da) |
TW (1) | TWI255184B (da) |
WO (1) | WO2000061145A1 (da) |
ZA (1) | ZA200108258B (da) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US20030064949A1 (en) * | 1998-02-17 | 2003-04-03 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
BR122014028365B8 (pt) * | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
DE10017480A1 (de) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
EP1280923A2 (en) * | 2000-04-28 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 14094, a human trypsin family member and uses thereof |
JP2003534292A (ja) | 2000-05-19 | 2003-11-18 | ジェネンテック・インコーポレーテッド | Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ |
US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
MXPA03003011A (es) * | 2000-10-05 | 2003-07-14 | George Q Daley | Metodos para inducir muerte de celulas cancerosas y regresion de tumores. |
AU2002236765A1 (en) * | 2001-01-16 | 2002-07-30 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
CN101220033A (zh) * | 2001-01-18 | 2008-07-16 | 先灵公司 | 替莫唑胺和类似物的合成 |
NZ516873A (en) * | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
US6703400B2 (en) | 2001-02-23 | 2004-03-09 | Schering Corporation | Methods for treating multidrug resistance |
US20030185831A1 (en) * | 2001-11-30 | 2003-10-02 | Schering Corporation | Methods of treating cancer using an FPT inhibitor and antineoplastic |
US20040006087A1 (en) * | 2001-12-03 | 2004-01-08 | Schering Corporation | Method of treating cancer using FPT inhibitors and antineoplastic agents |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
US6984389B2 (en) * | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
IL164799A0 (en) | 2002-04-25 | 2005-12-18 | Univ Connecticut | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
NZ571508A (en) * | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
US20060270643A1 (en) * | 2002-10-31 | 2006-11-30 | Chawnshang Chang | Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
EP1622942B1 (en) * | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
EP1691812A4 (en) | 2003-11-20 | 2010-01-13 | Childrens Hosp Medical Center | GTPASE INHIBITORS AND METHOD OF USE |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
AU2005209909B8 (en) * | 2004-02-03 | 2009-01-15 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
US7811562B2 (en) * | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
PT1850874E (pt) | 2005-02-23 | 2013-12-02 | Genentech Inc | Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
MX2007012896A (es) * | 2005-04-15 | 2007-12-10 | Schering Corp | Metodos y composiciones para tratamiento o prevencion de cancer. |
CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2006138315A2 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-igf1r antibody formulations |
US8128929B2 (en) * | 2005-06-17 | 2012-03-06 | Imclone Llc | Antibodies against PDGFRa |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
AP2008004569A0 (en) * | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
WO2008005469A2 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
MX2009004555A (es) * | 2006-10-25 | 2009-05-11 | Schering Corp | Metodos de tratamiento de cancer de ovario. |
PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
TW200845962A (en) | 2007-05-08 | 2008-12-01 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
EP2175885B1 (en) * | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
WO2009145852A1 (en) * | 2008-04-17 | 2009-12-03 | Concert Pharmaceuticals, Inc. | Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
WO2010048018A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
KR20140057326A (ko) | 2011-08-17 | 2014-05-12 | 제넨테크, 인크. | 뉴레귤린 항체 및 그의 용도 |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
BR112015012644A2 (pt) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; |
CA2946759A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
CA3236828A1 (en) | 2021-11-02 | 2023-05-11 | Semmelweis Egyetem | Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2546577B2 (de) | 1975-10-17 | 1981-04-02 | Sandoz-Patent-GmbH, 7850 Lörrach | Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden |
EP0214092A1 (en) | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
EP0411048A1 (en) | 1988-04-28 | 1991-02-06 | Schering Corporation | Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
US5393890A (en) | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
JPH06504772A (ja) * | 1990-12-18 | 1994-06-02 | ザ ウエルカム ファウンデーション リミテッド | 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤 |
WO1993020080A1 (en) | 1992-03-27 | 1993-10-14 | Schering Corporation | Bridged bis-aryl carbinol derivatives, compositions and methods of use |
US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
FR2698560B1 (fr) | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5661152A (en) | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
ATE210652T1 (de) | 1993-10-15 | 2001-12-15 | Schering Corp | Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen |
US5719148A (en) | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5464840A (en) | 1993-12-06 | 1995-11-07 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5523095A (en) | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
WO1996019200A1 (fr) | 1994-12-19 | 1996-06-27 | Daiichi Pharmaceutical Co., Ltd. | Preparation granulaire a liberation prolongee et procede de production |
US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
ATE302613T1 (de) | 1995-08-09 | 2005-09-15 | Banyu Pharma Co Ltd | Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
CN1326847C (zh) * | 1995-12-22 | 2007-07-18 | 先灵公司 | 三环酰胺类用于抑制g-蛋白功能及治疗增生疾病 |
JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
CA2251716A1 (en) | 1996-04-15 | 1997-10-23 | W. Gillies Mckenna | Sensitization of cells to radiation and chemotherapy |
EP0952842A2 (en) | 1996-04-18 | 1999-11-03 | Merck & Co., Inc. | A method of treating cancer |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
JP2000514057A (ja) | 1996-06-28 | 2000-10-24 | シェーリング コーポレイション | 増強されたバイオアベイラビリティを有する抗真菌剤の固溶体 |
US5972381A (en) | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
US5861395A (en) | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
US5965570A (en) | 1996-09-13 | 1999-10-12 | Schering Corporation | Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase |
US5958890A (en) | 1996-09-13 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6040305A (en) | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
IL128951A0 (en) | 1996-09-13 | 2000-02-17 | Schering Corp | Tricyclic compounds useful for inhibition of farnesyl protein transferase |
US5945429A (en) | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6071907A (en) | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
US5985879A (en) | 1996-09-13 | 1999-11-16 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
IL131447A0 (en) | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US5877177A (en) | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5925639A (en) | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
US5939416A (en) | 1997-06-17 | 1999-08-17 | Schering Corporation | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
US5852034A (en) | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
US5958940A (en) | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
EP1039908B1 (en) | 1997-12-22 | 2004-02-25 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
-
1999
- 1999-04-09 US US09/289,255 patent/US6316462B1/en not_active Expired - Fee Related
-
2000
- 2000-04-06 HU HU0200773A patent/HUP0200773A3/hu unknown
- 2000-04-06 DK DK00921765T patent/DK1165078T3/da active
- 2000-04-06 AR ARP000101576A patent/AR023400A1/es unknown
- 2000-04-06 WO PCT/US2000/009124 patent/WO2000061145A1/en active IP Right Grant
- 2000-04-06 BR BR0009670-9A patent/BR0009670A/pt not_active IP Right Cessation
- 2000-04-06 MX MXPA01010211A patent/MXPA01010211A/es active IP Right Grant
- 2000-04-06 JP JP2000610478A patent/JP2003529540A/ja active Pending
- 2000-04-06 PT PT00921765T patent/PT1165078E/pt unknown
- 2000-04-06 ES ES00921765T patent/ES2275505T3/es not_active Expired - Lifetime
- 2000-04-06 TW TW089106323A patent/TWI255184B/zh not_active IP Right Cessation
- 2000-04-06 NZ NZ514628A patent/NZ514628A/xx not_active IP Right Cessation
- 2000-04-06 AT AT00921765T patent/ATE347360T1/de not_active IP Right Cessation
- 2000-04-06 CA CA002364675A patent/CA2364675A1/en not_active Abandoned
- 2000-04-06 DE DE60032226T patent/DE60032226T2/de not_active Expired - Lifetime
- 2000-04-06 EP EP00921765A patent/EP1165078B1/en not_active Expired - Lifetime
- 2000-04-06 AU AU42041/00A patent/AU783177B2/en not_active Ceased
- 2000-04-06 CN CNB008085293A patent/CN100421661C/zh not_active Expired - Fee Related
- 2000-04-07 PE PE2000000317A patent/PE20010025A1/es not_active Application Discontinuation
- 2000-04-07 MY MYPI20001455A patent/MY120841A/en unknown
-
2001
- 2001-10-08 NO NO20014897A patent/NO329133B1/no not_active IP Right Cessation
- 2001-10-08 ZA ZA200108258A patent/ZA200108258B/xx unknown
-
2002
- 2002-01-09 HK HK02100132.7A patent/HK1038512B/zh not_active IP Right Cessation
-
2007
- 2007-03-01 CY CY20071100296T patent/CY1107545T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HK1038512A1 (en) | 2002-03-22 |
CN1364084A (zh) | 2002-08-14 |
NO20014897D0 (no) | 2001-10-08 |
WO2000061145A1 (en) | 2000-10-19 |
BR0009670A (pt) | 2002-01-15 |
MXPA01010211A (es) | 2002-09-18 |
US6316462B1 (en) | 2001-11-13 |
EP1165078A1 (en) | 2002-01-02 |
DE60032226T2 (de) | 2007-10-11 |
AU4204100A (en) | 2000-11-14 |
NO20014897L (no) | 2001-12-10 |
EP1165078B1 (en) | 2006-12-06 |
MY120841A (en) | 2005-11-30 |
HUP0200773A3 (en) | 2003-04-28 |
ES2275505T3 (es) | 2007-06-16 |
CN100421661C (zh) | 2008-10-01 |
AR023400A1 (es) | 2002-09-04 |
HUP0200773A2 (hu) | 2002-07-29 |
AU783177B2 (en) | 2005-09-29 |
ATE347360T1 (de) | 2006-12-15 |
ZA200108258B (en) | 2003-03-26 |
JP2003529540A (ja) | 2003-10-07 |
DE60032226D1 (de) | 2007-01-18 |
NZ514628A (en) | 2004-01-30 |
TWI255184B (en) | 2006-05-21 |
CA2364675A1 (en) | 2000-10-19 |
CY1107545T1 (el) | 2013-03-13 |
NO329133B1 (no) | 2010-08-30 |
HK1038512B (zh) | 2007-04-27 |
PE20010025A1 (es) | 2001-02-05 |
PT1165078E (pt) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1165078T3 (da) | Fremgangsmåder til induktion af cancercelledöd og tumorregression | |
IS2468B (is) | Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini | |
NO994069L (no) | Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav | |
NO20053817D0 (no) | Preparater og fremgangsmater for antiviral kombinasjonsterapi. | |
DK0972201T3 (da) | Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf | |
NO20021433L (no) | Vaksiner | |
NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
DK1576132T3 (da) | Nukleinsyrer benævnt 273p4b7 og anvendelse heraf til detektering af cancer | |
DE50015294D1 (de) | Mikrotom | |
IS6375A (is) | Lyfjagjöf til öftrunar á blöðruhálskrabbameini | |
DK1181397T3 (da) | Rhodium-elektrokatalysator og fremgangsmåde til fremstilling af denne | |
NO20031531D0 (no) | Fremgangsmåter for reduksjon av kreftcelledöd og tumorregresjon | |
NO20001554L (no) | FremgangsmÕter og mellomprodukter nyttige for Õ fremstille antifolater | |
EP1425399A4 (en) | COMBINATIVE METHODS FOR CELL DOD INDUCTION IN CANCER CELLS | |
IS6401A (is) | Efnafræðilegar aðferðir og milliefni | |
DK1083934T3 (da) | Genterapifremgangsmåder | |
NO20015242D0 (no) | Fremgangsmåte for påvisning og dreping av epiteliale kreftceller | |
PT1178981E (pt) | 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos | |
NO20021976L (no) | Selektiv leverterapi | |
IS6707A (is) | Efnablanda til forvarna og meðhöndlunar á krabbameini | |
NO20025343D0 (no) | FremgangsmÕte for Õ inhibere proliferasjon og for Õ indusere apoptose i cancerceller | |
NO20020291D0 (no) | Preventive og terapeutiske midler for kreft | |
ATA175499A (de) | Schmuckstück | |
SI1165078T1 (sl) | Postopki za induciranje smrti rakavih celic in regresijo tumorjev | |
DK1145011T3 (da) | Sammensætninger og fremgangsmåder til diagnosticering og behandling af tumor |